Drug industry representatives want more specifics on CMS’ timeline and process for considering feedback and proposing guidance to implement Medicare’s new drug price negotiation authority, and they hope CMS will flesh those specifics out during discussions with the industry Monday afternoon. CMS and drug companies are meeting Monday (Feb. 27) to discuss initial guidance the agency released this month on its implementation of the Inflation Reduction Act’s Part B and D inflation rebate provisions, which require drug companies pay Medicare...